Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 65-72 , 30 October 2009

Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain

Received 16 June 2009 ,Revised 14 August 2009 ,Accepted 14 August 2009.

References 

  1. Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J. Comp. Neurol. 1986;251:260–280
  2. Banks WA. Developing drugs that can cross the blood–brain barrier: applications to Alzheimer's disease. BMC Neurosci. 2008;9(Suppl 3):S2
  3. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood–brain barrier in a mouse model of Alzheimer's disease. Peptides. 2002;23:2223–2226
  4. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol. Scand. 1988;78:318–323
  5. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29:1326–1334
  6. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002;5:514–516
  7. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U. S. A. 2002;99:12432–12437
  8. Chung YB, Han K, Nishiura A, Lee VH. Ocular absorption of Pz-peptide and its effect on the ocular and systemic pharmacokinetics of topically applied drugs in the rabbit. Pharm. Res. 1998;15:1882–1887
  9. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2005;102:3811–3816
  10. Dhanda DS, Frey WH, Leopold D, Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv. Technol. 2005;5(4):
  11. Eyles JE, Williamson ED, Alpar HO. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int. J. Pharm. 1999;189:75–79
  12. Francis G, Martinez J, Liu W, Nguyen T, Ayer A, Fine J, et al. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes. 2009;58:934–945
  13. Frey WH. Bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. 2002;2(5):
  14. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009;45:55–57
  15. Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 2009;50:771–778
  16. Gross EA, Swenberg JA, Fields S, Popp JA. Comparative morphometry of the nasal cavity in rats and mice. J. Anat. 1982;135:83–88
  17. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 1989;170:607–612
  18. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000;11:1–18
  19. Katsuse O, Iseki E, Kosaka K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology. 2003;23:9–15
  20. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs. 2002;16:111–148
  21. Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 1999;162:254–262
  22. Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine. 1999;17:2036–2042
  23. Ma Y-P, Ma M-M, Ge S, Guo R-B, Zhang H-J, Frey WH, et al. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull. 2007;74:271–277
  24. Ma M, Ma Y, Yi X, Guo R, Zhu W, Fan X, et al. Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci. 2008;9:117–126
  25. Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 1991;32:67–74
  26. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994;165:208–210
  27. MSStudyGroup. TNF neutralization in MS results of a randomized, placebo-controlled multicenter study. Neurology. 1999;457–465
  28. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson`s disease. J. Neural. Transm. [Suppl.]. 2000;60:277–290
  29. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci. 2009;50:779–786
  30. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 1995;28:126–142
  31. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 1995;37:82–88
  32. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 1990;172:1193–1200
  33. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 1991;87:949–954
  34. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991;325:467–472
  35. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57:1885–1888
  36. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 2001;40:907–946
  37. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–496
  38. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience. 2008;152:785–797
  39. Thurber GM, Wittrup KD. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 2008;68:3334–3341
  40. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008;8:27–35
  41. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006;8:25
  42. Trolle S, Chachaty E, Kassis-Chikhani N, Wang C, Fattal E, Couvreur P, et al. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae. Vaccine. 2000;18:2991–2998
  43. Urech, D.M., Feige, U., Ewert, S., Schlosser, V., Ottiger, M., Polzer, K., Schett, G., Lichtlen, P., 2009. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-{alpha} scFv (ESBA105) designed for local therapeutic use. Ann Rheum Dis., Electronic publication ahead of print.
  44. Xiao BG, Bai XF, Zhang GX, Link H. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol. 1998;84:230–237
  45. Yang JP, Liu HJ, Cheng SM, Wang ZL, Cheng X, Yu HX, et al. Direct transport of VEGF from the nasal cavity to brain. Neurosci. Lett. 2009;449:108–111
  46. Yen W-C, Lee VHL. Paracellular transport of a proteolytically labile pentapeptide across the colonic and other intestinal segments of the albino rabbit: implications for peptide drug design. J. Control. Release. 1994;28:97–109
  47. Yen W-C, Lee VHL. Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers. J. Control. Release. 1995;36:25–37

PII: S0165-5728(09)00310-5

doi: 10.1016/j.jneuroim.2009.08.005

Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 65-72 , 30 October 2009

Article Tools

* Image Usage & Resolution